Spruce Biosciences Inc. (SPRB)
NASDAQ: SPRBHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SPRB stock chart
Technical analysisKey statistics
All statistics- Market cap
- $109.21M
- Forward P/E
- 11.79
- EPS (TTM)
- -$33.29
- Dividend yield
- None
- 52-week range
- 38.00 – 111.00
- Day range
- 38.00 – 40.96
- Volume / Avg
- 108.28K / 89.33K
- Beta
- —
- Shares outstanding
- 2.87M
52-week range
SPRB stock today
Spruce Biosciences (SPRB) closed at $38.00 on Nov 20, down 6.15% (-$2.49), versus the S&P 500's 3.70% decline. Shares are 65.8% below their 52-week high of $111.00 and 0.0% above the 52-week low of $38.00, near the bottom of the past year's range. SPRB is down 56.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 63.8%.
Spruce Biosciences has posted a net loss over the last twelve months (EPS of -$33.29), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Spruce Biosciences
Company profileSpruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Javier Szwarcberg M.D., M.P.H.
- Headquarters
- South San Francisco, CA
- Employees
- 25
- IPO year
- 2020
- Website
- sprucebio.com
Financial highlights
Full financialsIn fiscal 2025, Spruce Biosciences generated $0 in revenue, down 100.0% from fiscal 2024, its first annual decline since 2024. Spruce Biosciences reported a net loss of $39.0 million, compared with a loss of $53.0 million a year earlier. Diluted earnings per share came in at -$50.83.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $4.91M | $10.09M | $0 | — |
| Growth | -100.00% | -51.32% | — | — | — |
| Net income | $-38.97M | $-53.04M | $-47.92M | $-46.18M | $-42.29M |
| EPS (diluted) | $-50.83 | $-96.40 | $-1.24 | $-1.96 | $-1.81 |
Analyst forecast
ForecastConsensus (9 analysts)
strong_buy
Avg. price target
$147.44+288.00%
- Strong buy 1
- Buy 8
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-8.51 vs $-5.76
- Surprise
- -47.74%
SPRB news
All SPRB newsSpruce Biosciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BGMBGM Group Ltd. Class A | 8.13 | 0.00% | $108.57M | vs SPRB |
| MENSJyong Biotech Ltd. | 1.45 | -17.14% | $110.24M | vs SPRB |
| IMUXImmunic Inc. | 6.99 | -5.41% | $111.01M | vs SPRB |
| OKUROnKure Therapeutics Inc. Class A | 2.70 | -2.17% | $111.21M | vs SPRB |
| AKBAAkebia Therapeutics Inc. | 0.3855 | -8.71% | $107.04M | vs SPRB |
| GNLXGenelux Corporation | 2.17 | -4.82% | $103.36M | vs SPRB |
| FHTXFoghorn Therapeutics Inc. | 1.72 | -3.37% | $103.14M | vs SPRB |
| ADAGAdagene Inc. ADR | 1.76 | -12.44% | $118.17M | vs SPRB |
Indexes, lists and sector
Spruce Biosciences stock FAQ
What is Spruce Biosciences's stock price today?
SPRB last traded at $38.00 as of Nov 20, 4:00 PM EST, down 6.15% on the day. Prices are delayed at least 15 minutes.
Does Spruce Biosciences pay a dividend?
No. Spruce Biosciences does not currently pay a regular cash dividend.
Who is Spruce Biosciences's CEO?
Dr. Javier Szwarcberg M.D., M.P.H. is the chief executive officer of Spruce Biosciences Inc., which has about 25 employees.
Has SPRB ever split its stock?
Yes. The most recent SPRB stock split was a 1-for-75 split on Aug 7, 2025, one of 2 splits on record.
What is the SPRB 52-week high?
The 52-week high for SPRB is $111.00 and the 52-week low is $38.00. The stock is currently 65.8% below its high.